GLP-1 receptor agonists hold potential to treat opioid use disorder, says GlobalData
A recent Phase I clinical study conducted at the Caron Treatment Centers in Pennsylvania has demonstrated the potential of Novo Nordisk’s Saxenda (liraglutide), a GLP-1 receptor ag...
Read →